Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,967,600.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $75,534,196.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

  • On Friday, November 13th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $100.38, for a total transaction of $2,007,600.00.
  • On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.58, for a total transaction of $2,191,600.00.
  • On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00.
  • On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00.
  • On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $107.24, for a total value of $2,144,800.00.
  • On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00.

Halozyme Therapeutics Trading Down 3.8%

HALO traded down $3.77 during trading on Monday, hitting $96.50. 2,088,290 shares of the stock were exchanged, compared to its average volume of 2,352,912. The firm has a 50 day simple moving average of $114.29 and a 200 day simple moving average of $85.63. The firm has a market cap of $11.00 billion, a price-to-earnings ratio of 18.07, a P/E/G ratio of 0.38 and a beta of 0.92. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $134.00. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 751.81% and a net margin of 26.93%. The business had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same period in the previous year, the company posted $1.72 EPS. Halozyme Therapeutics’s revenue was up 39.1% on a year-over-year basis. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of HALO. Bank of America Corp DE purchased a new position in Halozyme Therapeutics during the 2nd quarter worth $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the second quarter worth about $196,540,000. Jupiter Topco LLC acquired a new stake in Halozyme Therapeutics in the second quarter worth about $105,570,000. Caisse de depot et placement du Quebec purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth about $83,940,000. Finally, Congress Asset Management Co. grew its stake in shares of Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HALO has been the topic of several recent research reports. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b+)” rating in a report on Monday, November 9th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $108.18.

View Our Latest Research Report on Halozyme Therapeutics

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Featured Articles

Insider Buying and Selling by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.